A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants with lung cancer or pleural mesothelioma

  • Park, John (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Tan, Pearlyn (Clinical Trial Unit Staff)

Project: Research

Project Details

Effective start/end date13/05/2115/04/26